POPULARITY
12 episodes with Drug resistance
8 episodes with Drug resistance
2 episodes with Drug resistance
3 episodes with Drug resistance
3 episodes with Drug resistance
2 episodes with Drug resistance
4 episodes with Drug resistance
2 episodes with Drug resistance
2 episodes with Drug resistance
HIV research is one of the clearest examples of molecular biology in action. In this Mol Bio Minutes episode, Dr. Ryan Jeep walks through how fundamental molecular techniques power everything from detection to drug resistance studies to cure-focused research. Ryan begins with HIV biology and detection, explaining how qRT-PCR enables highly sensitive viral load measurement. These assays not only detection strategies but also support research to monitor treatment efficacy and viral rebound. From there, he moves into drug resistance, describing how sequencing, RT-PCR, and cloning strategies help researchers map resistance-associated mutations. By generating recombinant reporter viruses and measuring infectivity against different drugs, scientists can better understand treatment failure and move toward more personalized therapeutic strategies. Finally, Ryan explores cutting-edge cure research, including CRISPR-Cas9 approaches aimed at either disabling integrated viral genomes or engineering HIV-resistant immune cells. Across all three areas one theme remains constant: PCR, sequencing, and cloning form the technological backbone of HIV research. As these tools continue to evolve, so too does the potential to improve outcomes and one day eliminate the virus entirely. Since recording this episode, Ryan has joined KBI Biopharma as a Scientist l in their Formulation Development Group. Helpful resources and links: Access Stanford University's HIV Drug Resistance Database. Visit International AIDS Society's Towards an HIV Cure site, which includes resources. Access Thermo Fisher PCR resources and products. Learn about RT-qPCR, which is relevant to HIV research. Explore the cloning technologies referenced in this episode. Subscribe to get future episodes as they drop and if you like what you're hearing we hope you'll share a review or recommend the series to a colleague. Visit the Invitrogen School of Molecular Biology to access helpful molecular biology resources and educational content, and please share this resource with anyone you know working in molecular biology. For Research Use Only. Not for use in diagnostic procedures.
After a life-changing accident, Vanessa spent years fighting a dangerous infection that kept coming back. Eventually, doctors discovered why: the bacteria fueling it were resistant to antibiotics. Her story leads us far beyond the hospital, into waterways, soils, and a hidden world where the medicines meant to save us may be helping create the next superbugs.
"Our goal of precision oncology has been to shift to tailored therapies that can help to improve treatment efficacy and ultimately improve patient outcomes. Resistance biomarker testing can help the care team to detect these genomic changes that the tumor may have acquired during therapy that makes the cells resistant to therapy. This information can be extremely helpful when we're talking about making choices about second-line or subsequent-line therapy," ONS member Danielle Fournier, DNP, APRN, AGPCNP-BC, AOCNP®, advanced practice RN at the University of Texas MD Anderson Cancer Center in Houston, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about drug resistance biomarker testing. This podcast episode is sponsored by AstraZeneca. ONS is solely responsible for the criteria, objectives, content, quality, and scientific integrity of its programs and publications. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Episode Notes This episode is not eligible for NCPD credit. ONS Podcast™ episodes: Episode 389: Biomarker Testing for Non-Small Cell Lung Cancer Episode 373: Biomarker Testing in Prostate Cancer Episode 169: How Biomarker Testing Drives the Use of Targeted Therapies ONS Voice articles: Help Your Patients Understand Biomarker Resistance Testing Key Patient Education Points for Biomarker Resistance Testing Quick Quiz: How Much Do You Know About Drug Resistance in Cancer? Quick Quiz: How Much Do You Know About Somatic Biomarker Resistance Testing? When Targeted Therapy Stops Working, What's Next? Discover How Biomarker Resistance Testing Opens New Doors ONS Biomarker Database Clinical Journal of Oncology Nursing article: Tumor-Agnostic Therapies Reshaping Cancer Care ONS book: Understanding Genomic and Hereditary Cancer Risk: A Handbook for Oncology Nurses ONS course: Genomic Foundations for Precision Oncology ONS Genomics and Precision Oncology Learning Library American Cancer Society Cancer Action Network: Access to Biomarker Testing page White paper: The Landscape of Biomarker Testing Coverage in the United States Find out which states are currently discussing biomarker testing bills and how you can advocate for them through ONS. To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "We know that biomarkers are playing an ever more important role in cancer care, and really, their use can range anywhere from helping us to confirm a given diagnosis, understand a patient's cancer susceptibility or risk, evaluate prognosis, as well as personalize treatment recommendations. … But in some cases, though, biomarkers can also help us to avoid therapies that are not likely to work. We also call these drug resistance biomarkers. These are those biomarkers that signify that a tumor is unlikely to respond to a given therapy." TS 1:50 "Resistance to cancer therapies is one of the most common issues that arises during cancer treatment. Because the populations of cancer cells within a tumor can be very diverse, when a given drug kills the cells that are sensitive to that therapy, it can also eventually leave behind resistant tumor cells, which can grow and multiply over time. So this can ultimately lead to a point where the treatment that was initially effective is no longer able to control the disease." TS 4:33 "While costs have come down, there can still be a cost associated with biomarker testing, and in some cases, this can be considered a barrier to care. What patients pay out of pocket can vary widely depending on their insurance coverage. So we have some data that was published from the American Cancer Society Cancer Action Network, and this was published a few years ago in 2023, which showed the average allowed unit cost to insurers per biomarker test ranged anywhere from about $79 for patients who were on Medicaid to about $224 for large-group, self-insured patients." TS 10:03 "There's research underway that's looking not only at genomic changes—so DNA changes that impact drug resistance—but how other substances such as RNA and proteins within the cell can also contribute to drug resistance. And this kind of falls into not just genomics but multiomics field. I have no doubt whatsoever that the use of artificial intelligence and machine learning is likely going to play a large role in drug resistance research. And really, these tools can help researchers to analyze complex data sets, identify novel resistance biomarkers, predict resistance patterns, as well as help to develop treatments that may overcome some of those resistance mechanisms." TS 17:00
Send a textImagine this scene:A family's house was destroyed when it was bombed during a war. They got out with the clothes on their backs – nothing more. When they were fleeing, the mother was hit with fragments from another bomb. It tore off part of her leg. Dirt got in the wound.They made it to a refugee camp, but the wound got infected. With nothing available to treat the injury, the infection got worse. She had a drug-resistant infection that wasn't treatable with regular antibiotics. Her entire leg and part of her hip had to be removed to save her life. She will have a physical disability for the rest of her life.This is just one story of drug resistance or antimicrobial resistance (AMR) and the impact of armed conflict. Report after report finds that victims of armed conflict and refugees – both those seeking shelter abroad and inside their own countries – are especially likely to suffer from drug-resistant infections.Dr. Aula Abbara, Consultant in Infectious Diseases and Acute Medicine and Honorary Senior Clinical Lecturer at Imperial College, London, has been studying the problem firsthand.She's worked with teams that found people injured in Syria's 15-year-long conflict not only suffered terrible wounds, but then developed worse infections because of crowded and unsanitary conditions in healthcare facilities. These war-damaged hospital laboratories in Syria, especially, lacked the capacity to test for drug-resistant bacteria, and so doctors didn't know which antibiotics to prescribe to treat patients' infections.Solutions require taking a One Health approach, Dr. Abbara and colleagues have found.She and her colleagues call for programs to bring in more health professionals and healthcare access; introduction of easy-to-use diagnostics so people's infections can be immediately diagnosed and thus treated with the correct drugs; stopping the improper use and distribution of antibiotics; and proper surveillance so that professionals know which drug-resistant infections are spreading and where.In this episode of One World, One Health, Dr. Abbara chats with host Maggie Fox about what she's seen and what might help.
Malaria exerts a devastating impact on communities in the Global South, with upwards of 600,000 deaths yearly, primarily young African children. Using genetic approaches, we have explored the molecular basis of Plasmodium falciparum antimalarial drug resistance, which poses a constant threat to malaria treatment and control efforts. Using a genetic cross, we earlier identified that mutations in PfCRT conferred parasite resistance to chloroquine, the former first-line antimalarial drug. Structural and functional studies reveal that these mutations enable this transporter of globin-derived peptides to efflux chloroquine away from its heme target in parasitized erythrocytes. We also identified novel PfCRT variants that mediate resistance to piperaquine, a first-line combination partner drug that recently failed across Southeast Asia. We and others have also shown that mutations in Kelch13 are causal for parasite resistance to artemisinin, the core component of all current combination therapies, and have identified their emergence in east Africa. Kelch13 mutations affect multiple intracellular processes including hemoglobin endocytosis and degradation, mitochondrial physiology, and artemisinin-induced cellular quiescence. In anticipation that artemisinin partial resistance will lead to this drug becoming ineffective at treating severe malaria, we also have also leveraged a genetic cross to explore parasite susceptibility to quinine, an alternative treatment for severe disease. This work has identified a novel drug-metabolite transporter, DMT1, as a novel determinant of quinine resistance. Our ongoing efforts to identify new therapeutic approaches to treating artemisinin-resistant malaria include developing parasite-specific proteasome inhibitors, which synergize with artemisinin and restore its activity including against resistant parasites. Insights gained into molecular resistance mechanisms and genetic markers are being incorporated into global efforts to mitigate the emergence and spread of multidrug-resistant malaria.
Drug resistance derails even the most advanced cancer treatments, but what if we could restore sensitivity to existing therapies instead of starting over? Neil Bhowmick, chief scientific officer at Kairos Pharma, joins In Vivo to discuss how his company is tackling resistance in oncology. We explore the company's lead asset, ENV-105, which is showing over 13 months of progression-free survival in Phase II prostate cancer trials by resensitizing tumors to hormone therapy, with significantly lower toxicity than standard alternatives like chemotherapy or radiopharmaceuticals. Bhowmick explains the complex biology behind different resistance mechanisms, shares early data on GITR-modulating therapies designed to expand T cell populations for immunotherapy, and discusses their approach to developing companion biomarkers for patient selection. We also dive into the clinical and commercial rationale for combination approaches and what milestones to watch in the coming year.
In this episode, Catherine Glass is joined by Anna Minchom, Clinical Scientist at the Drug Development Unit at the Royal Marsden Hospital and the Institute of Cancer Research, London, UK. In a highly informative discussion, Minchom explains the drug development process, key considerations in designing and conducting a trial, and the challenges in drug resistance. Timestamps: 00:00 – Introduction 00:51 – Her journey into oncology 4:04 – Drug development 07:20 – Patient recruitment 08:45 – Challenges of drug resistance 11:20 – Early-phase clinical trials 13:06 – Navigating clinical trial outcomes 15:38 – Emerging technologies and therapies 17:42 – Side effects 19:09 – Three magic wishes
Overview: In this episode, Dr Joel Gallant gives a history of antiretroviral therapy and HIV drug resistance, drawing on his personal and professional experience beginning in the early 1980s. The views expressed are those of the panelist and not necessarily Gilead Sciences, Inc. The information provided in this podcast is not intended to be and should not be understood to provide medical advice. Listeners should note that our discussions in this episode are relevant to the USA only and may not be appropriate for other regions. This episode was recorded in August 2023 and the content reflects the information available at that time. Guest: Joel Gallant, MD, MPH For more information, please visit: https://www.pri-med.com/clinical-resources/curriculum/hiv-in-focus References AIDSVu.org. New HIV diagnoses. 2023. Available from: https://aidsvu.org/local-data/united-states/south/ (Accessed May 19, 2025) AIDSVu.org was developed by the Rollins School of Public Health at Emory University in partnership with Gilead Sciences, Inc. Alonso A, de Irala J. Strategies in HIV prevention: the A-B-C approach. Lancet 2004;364:1033. Available from: https://doi.org/10.1016/s0140-6736(04)17050-5 Bacheler L, Jeffrey S, Hanna G et al. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J Virol 2001;75:4999–5008. Available from: https://doi.org/10.1128/jvi.75.11.4999-5008.2001 Barré-Sinoussi F, Chermann JC, Rey F et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983;220:868–71. Available from: https://doi.org/10.1126/science.6189183 Bayer R, Edington C. HIV testing, human rights, and global AIDS policy: exceptionalism and its discontents. J Health Polit Policy Law 2009;34:301–23. Available from: https://doi.org/10.1215/03616878-2009-002 Centers for Disease Control and Prevention. Pneumocystis pneumonia – Los Angeles. MMWR Morb Mortal Wkly Rep 1981;30:250-2. Available from: https://www.cdc.gov/mmwr/preview/mmwrhtml/june_5.htm Centers for Disease Control and Prevention. Preventing HIV. 2024. Available from: https://www.cdc.gov/hiv/prevention/index.html (Accessed May 22, 2025) Cohen MS, Chen YQ, McCauley M et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011;365:493–505. Available from: https://doi.org/10.1056/NEJMoa1105243 Cuevas JM, Geller R, Garijo R et al. Extremely high mutation rate of HIV-1 in vivo. PLoS Biol 2015;13:e1002251. Available from: https://doi.org/10.1371/journal.pbio.1002251 Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. 2024. Available from: https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/optimizing-antiretroviral-therapy (Accessed May 19, 2025) Dragovic G. Acute pancreatitis in HIV/AIDS patients: an issue of concern. Asian Pac J Trop Biomed 2013;3:422–425. Available from: https://doi.org/10.1016%2FS2221-1691(13)60091-X Eron JJ, Benoit SL, Jemsek J et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party. N Engl J Med 1995;333:1662–9. Available from: https://doi.org/10.1056/nejm199512213332502 Gandhi RT, Tashima KT, Smeaton LM et al. Long-term outcomes in a large randomized trial of HIV-1 salvage therapy: 96-week results of AIDS clinical trials group A5241 (OPTIONS). J Infect Dis 2020;221:1407–15. Available from: https://doi.org/10.1093/infdis/jiz281 Getting to Zero San Francisco. HIV epidemiology annual report 2017. 2022. Available from: https://gettingtozerosf.org/getting-to-zero-resources/hiv-report-2017/ (Accessed May 22, 2025) Global Fund. About the Global Fund. 2024. Available from: https://www.theglobalfund.org/en/about-the-global-fund/ (Accessed May 19, 2025) Gulick RM, Lalezari J, Goodrich J et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008;359:1429–41. Available from: https://doi.org/10.1056/NEJMoa0803152 Gulick RM, Mellors JW, Havlir D et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734–9. Available from: https://doi.org/10.1056/nejm199709113371102 Haubrich R, Berger D, Chiliade P et al. Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. AIDS 2007;21:F11–8. Available from: https://doi.org/10.1097/QAD.0b013e3280b07b47 HIV Prevention Trials Network. HPTN 052. 2023. Available from: https://www.hptn.org/research/studies/hptn052 (Accessed May 19, 2025) HIV.gov. HIV and AIDS timeline. 2024. Available from: https://www.hiv.gov/hiv-basics/overview/history/hiv-and-aids-timeline/ (Accessed May 19, 2025) HIVinfo.NIH.gov. FDA approval of HIV medicines. 2024. Available from: https://hivinfo.nih.gov/understanding-hiv/infographics/fda-approval-hiv-medicines (Accessed May 19, 2025) i-base. Cross-resistance by drug class. 2025. Available from: https://i-base.info/guides/changing/cross-resistance (Accessed May 19, 2025) Iyidogan P, Anderson KS. Current perspectives on HIV-1 antiretroviral drug resistance. Viruses 2014;6:4095–139. Available from: https://doi.org/10.3390/v6104095 Lalezari JP, Henry K, O'Hearn M et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003;348:2175–85. Available from: https://doi.org/10.1056/NEJMoa035026 Landovitz RJ, Donnell D, Clement ME et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med 2021;385:595–608. Available from: https://doi.org/10.1056/NEJMoa2101016 Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989;243:1731–4. Available from: https://doi.org/10.1126/science.2467383 Lau B, Gange SJ, Moore RD. Risk of non-AIDS-related mortality may exceed risk of AIDS-related mortality among individuals enrolling into care with CD4+ counts greater than 200 cells/mm3. J Acquir Immune Defic Syndr 2007;44:179–87. Available from: https://doi.org/10.1097/01.qai.0000247229.68246.c5 Lucas C. The San Francisco model and the nurses of Ward 5B. Lancet HIV 2019;6:E819. Available from: https://doi.org/10.1016/S2352-3018(19)30267-X Madruga JV, Cahn P, Grinsztejn B et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007;370:29–38. Available from: https://doi.org/10.1016/s0140-6736(07)61047-2 Marcelin AG. Resistance to nucleoside reverse transcriptase inhibitors. In: Geretti AM, editor. Antiretroviral Resistance in Clinical Practice. London: Mediscript; 2006. Chapter 1. Available from: https://www.ncbi.nlm.nih.gov/books/NBK2241/ Margolis AM, Heverling H, Pham PA et al. A review of the toxicity of HIV medications. J Med Toxicol 2014;10:26–39. Available from: https://doi.org/10.1007/s13181-013-0325-8 Moore RD, Creagh-Kirk T, Keruly J et al. Long-term safety and efficacy of zidovudine in patients with advanced human immunodeficiency virus disease. Zidovudine Epidemiology Study Group. Arch Intern Med 1991;151:981–6. Available from: https://doi.org/10.1001/archinte.1991.00400050123023 National Institute of Allergy and Infectious Diseases. HIV Undetectable = Untransmittable (U = U), or treatment as prevention. 2019. Available from: https://www.niaid.nih.gov/diseases-conditions/treatment-prevention (Accessed May 19, 2025) Nelson MR, Katlama C, Montaner JS et al. The safety of […] for the treatment of HIV infection in adults: the first 4 years. AIDS 2007;21:1273–81. Available from: https://doi.org/10.1097/QAD.0b013e3280b07b33 New York State Department of Health. Pre-exposure prophylaxis (PrEP) to prevent HIV infection: question and answers. 2012. Available from: https://www.health.ny.gov/publications/0265/ (Accessed May 22, 2025) Overton ET, Richmond G, Rizzardini G et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with human immunodeficiency virus 1 type 1 infection: 152-week results from ATLAS-2M, a randomized, open-label, phase 3b, noninferiority study. Clin Infect Dis 2023;76:1646–54. Available from: https://doi.org/10.1093/cid/ciad020 Pollak EB, Parmar M. Indinavir. In: StatPearls. Treasure Island (FL): StatPearls Publishing, 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554396/ (Accessed May 19, 2025) Richman DD, Fischl MA, Grieco MH et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 1987;317:192–7. Available from: https://doi.org/10.1056/nejm198707233170402 Schmit JC, Ruiz L, Clotet B et al. Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538). AIDS 1996;10:995–9. Available from: https://doi.org/10.1097/00002030-199610090-00010 Siliciano JD, Kajdas J, Finzi D et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 2003;9:727–8. Available from: https://doi.org/10.1038/nm880 Steigbigel RT, Cooper DA, Kumar PN et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008;359:339–54. Available from: https://doi.org/10.1056/NEJMoa0708975 TIME. Man of the year. 1996. Available from: https://time.com/vault/issue/1996-12-30/page/1/ (Accessed May 19, 2025) U.S. President's Emergency Plan for AIDS Relief (PEPFAR). About us. 2025. Available from: https://www.state.gov/about-us-pepfar/ (Accessed May 19, 2025)
Detectable HIV-1 RNA (viral load) can seem very worrisome for people living with HIV who are receiving antiretroviral therapy (ART) and for their healthcare professionals. Tune in to learn how Brian R. Wood, MD, differentiates HIV-1 RNA “blips” from persistent low-level viremia and from virologic failure, and how he handles each scenario.Presenter:Brian R. Wood, MDProfessor of MedicineDivision of Allergy and Infectious DiseasesUniversity of WashingtonSeattle, WashingtonLink to full program: https://bit.ly/4nS7rYEGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Scott A. Armstrong, M.D., Ph.D., of the Dana-Farber Cancer Institute, studies how certain aggressive forms of acute myeloid leukemia (AML) develop and survive. His work centers on a protein called menin, which helps leukemia cells keep cancer-promoting genes switched on. Armstrong's team has found that blocking menin with specially designed drugs can shut down these gene programs, push leukemia cells to mature, and slow or stop the disease in lab models and patients. While some leukemias adapt by developing mutations in menin or finding other ways to survive, his research is revealing why certain genes are especially dependent on menin and how to target them more effectively. These discoveries are now shaping new treatments, drug combinations, and potential strategies for other cancers that rely on similar mechanisms. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40875]
Scott A. Armstrong, M.D., Ph.D., of the Dana-Farber Cancer Institute, studies how certain aggressive forms of acute myeloid leukemia (AML) develop and survive. His work centers on a protein called menin, which helps leukemia cells keep cancer-promoting genes switched on. Armstrong's team has found that blocking menin with specially designed drugs can shut down these gene programs, push leukemia cells to mature, and slow or stop the disease in lab models and patients. While some leukemias adapt by developing mutations in menin or finding other ways to survive, his research is revealing why certain genes are especially dependent on menin and how to target them more effectively. These discoveries are now shaping new treatments, drug combinations, and potential strategies for other cancers that rely on similar mechanisms. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40875]
Scott A. Armstrong, M.D., Ph.D., of the Dana-Farber Cancer Institute, studies how certain aggressive forms of acute myeloid leukemia (AML) develop and survive. His work centers on a protein called menin, which helps leukemia cells keep cancer-promoting genes switched on. Armstrong's team has found that blocking menin with specially designed drugs can shut down these gene programs, push leukemia cells to mature, and slow or stop the disease in lab models and patients. While some leukemias adapt by developing mutations in menin or finding other ways to survive, his research is revealing why certain genes are especially dependent on menin and how to target them more effectively. These discoveries are now shaping new treatments, drug combinations, and potential strategies for other cancers that rely on similar mechanisms. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40875]
Scott A. Armstrong, M.D., Ph.D., of the Dana-Farber Cancer Institute, studies how certain aggressive forms of acute myeloid leukemia (AML) develop and survive. His work centers on a protein called menin, which helps leukemia cells keep cancer-promoting genes switched on. Armstrong's team has found that blocking menin with specially designed drugs can shut down these gene programs, push leukemia cells to mature, and slow or stop the disease in lab models and patients. While some leukemias adapt by developing mutations in menin or finding other ways to survive, his research is revealing why certain genes are especially dependent on menin and how to target them more effectively. These discoveries are now shaping new treatments, drug combinations, and potential strategies for other cancers that rely on similar mechanisms. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40875]
Scott A. Armstrong, M.D., Ph.D., of the Dana-Farber Cancer Institute, studies how certain aggressive forms of acute myeloid leukemia (AML) develop and survive. His work centers on a protein called menin, which helps leukemia cells keep cancer-promoting genes switched on. Armstrong's team has found that blocking menin with specially designed drugs can shut down these gene programs, push leukemia cells to mature, and slow or stop the disease in lab models and patients. While some leukemias adapt by developing mutations in menin or finding other ways to survive, his research is revealing why certain genes are especially dependent on menin and how to target them more effectively. These discoveries are now shaping new treatments, drug combinations, and potential strategies for other cancers that rely on similar mechanisms. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40875]
Scott A. Armstrong, M.D., Ph.D., of the Dana-Farber Cancer Institute, studies how certain aggressive forms of acute myeloid leukemia (AML) develop and survive. His work centers on a protein called menin, which helps leukemia cells keep cancer-promoting genes switched on. Armstrong's team has found that blocking menin with specially designed drugs can shut down these gene programs, push leukemia cells to mature, and slow or stop the disease in lab models and patients. While some leukemias adapt by developing mutations in menin or finding other ways to survive, his research is revealing why certain genes are especially dependent on menin and how to target them more effectively. These discoveries are now shaping new treatments, drug combinations, and potential strategies for other cancers that rely on similar mechanisms. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40875]
Scott A. Armstrong, M.D., Ph.D., of the Dana-Farber Cancer Institute, studies how certain aggressive forms of acute myeloid leukemia (AML) develop and survive. His work centers on a protein called menin, which helps leukemia cells keep cancer-promoting genes switched on. Armstrong's team has found that blocking menin with specially designed drugs can shut down these gene programs, push leukemia cells to mature, and slow or stop the disease in lab models and patients. While some leukemias adapt by developing mutations in menin or finding other ways to survive, his research is revealing why certain genes are especially dependent on menin and how to target them more effectively. These discoveries are now shaping new treatments, drug combinations, and potential strategies for other cancers that rely on similar mechanisms. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40875]
Scott A. Armstrong, M.D., Ph.D., of the Dana-Farber Cancer Institute, studies how certain aggressive forms of acute myeloid leukemia (AML) develop and survive. His work centers on a protein called menin, which helps leukemia cells keep cancer-promoting genes switched on. Armstrong's team has found that blocking menin with specially designed drugs can shut down these gene programs, push leukemia cells to mature, and slow or stop the disease in lab models and patients. While some leukemias adapt by developing mutations in menin or finding other ways to survive, his research is revealing why certain genes are especially dependent on menin and how to target them more effectively. These discoveries are now shaping new treatments, drug combinations, and potential strategies for other cancers that rely on similar mechanisms. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40875]
Scott A. Armstrong, M.D., Ph.D., of the Dana-Farber Cancer Institute, studies how certain aggressive forms of acute myeloid leukemia (AML) develop and survive. His work centers on a protein called menin, which helps leukemia cells keep cancer-promoting genes switched on. Armstrong's team has found that blocking menin with specially designed drugs can shut down these gene programs, push leukemia cells to mature, and slow or stop the disease in lab models and patients. While some leukemias adapt by developing mutations in menin or finding other ways to survive, his research is revealing why certain genes are especially dependent on menin and how to target them more effectively. These discoveries are now shaping new treatments, drug combinations, and potential strategies for other cancers that rely on similar mechanisms. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40875]
Send us a textDrug-resistant germs are hidden killers in more than one way. Not only are the microbes invisible to the human eye, in many places, they're invisible because people simply are not looking for them systematically.Doctors often do not know what infections their patients have and treat them based on best guesses, which allows for ineffective treatments and exacerbates drug resistance. Policymakers don't know which infections are most common among populations and cannot make informed decisions about needed treatments or vaccines.This is a major problem across Africa and a new report shows just how complex the problem is.The Mapping AMR and Antimicrobial use Partnership (MAAP), which included the One Health Trust as well as the African Society for Laboratory Medicine; Africa CDC; the East, Central, and Southern Africa Health Community; Innovative Support to Emergencies, Diseases, and Disasters, a nonprofit focused on technology and communication; the clinical research group IQVIA; and the West African Health Organization, collected data from laboratories from 14 countries in Africa (Burkina Faso, Cameroon, Gabon, Ghana, Kenya, Eswatini, Malawi, Nigeria, Senegal, Sierra Leone, Tanzania, Uganda, Zambia, and Zimbabwe). “The study revealed significant gaps in bacteriology testing capacities,” the group, whose work was paid for by the UK government's Fleming Fund, wrote in PLoS Medicine.It's the biggest survey yet of testing for antimicrobial resistance – AMR or drug resistance – in Africa.Among the gaps: too little testing overall, a lack of laboratory capacities, and poor coordination and analysis of records. Many records were kept only on paper, which made them almost impossible to access.None of this surprises Dr. Sabiha Essack, South African Research Chair in Antibiotic Resistance and One Health and Professor in Pharmaceutical Sciences at the University of KwaZulu-Natal. In an ideal world, she says, a doctor, nurse or other professional should see a patient, test them to see what specific microbe is causing an infection, check to see which drugs will successfully fight that germ, and then treat the patient accordingly.Cheap point-of-care tests should be available everywhere and the results of those tests should be entered into systems that officials can use to make policy decisions, she says. Listen as she tells One World, One Health host Maggie Fox other ways to improve our knowledge about the drug-resistant infections that lurk out there. Want to know more? You can find One World, One Health episodes on drug-resistant infections in cancer patients; superbugs and microplastics; the personal toll of antibiotic resistance; one woman's antibiotic resistance nightmare; how to prevent drug resistance, and more.
Drug-resistant bacteria are a growing global threat — an invisible pandemic impacting millions each year. In this episode of Med School Minutes, Dr. Alya Limayem, Associate Professor at the University of North Florida and pioneer in nanotechnology research, shares how nano-based solutions could be the key to fighting superbugs.From her journey in science to her patented nanocompounds, Dr. Limayem discusses the urgent need for innovation, the promise of nanomedicine, and how even small-scale labs can make a big impact in global health.00:00 – Intro00:30 – Meet Dr. Alya Limayem02:55 – What Is Nanotechnology?04:02 – The Drug Resistance Crisis05:19 – Patents & Breakthroughs06:10 – Medical & Environmental Uses of Nanotech09:47 – Indigenous vs. Generic Probiotics10:57 – Balancing Teaching and Research15:10 – Starting Small in Research17:33 – Perseverance & Innovation18:59 – Journey from Tunisia to the U.S.27:39 – Building Research in the Caribbean#MedSchoolMinutes #SaintJamesSchoolOfMedicine #Nanotechnology #DrugResistance #MedicalResearch #Nanomedicine #Superbugs #GlobalHealth #CaribbeanMedicine #HealthcareInnovation #SciencePodcast #MedicalEducation
PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/XAS865. CME credit will be available until 30 July 2026.Revisiting HIV Antiretroviral Drug Resistance in the Current Landscape: Expert Insights Into Cause, Consequence, and Clinical Approaches for Management In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/XAS865. CME credit will be available until 30 July 2026.Revisiting HIV Antiretroviral Drug Resistance in the Current Landscape: Expert Insights Into Cause, Consequence, and Clinical Approaches for Management In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/XAS865. CME credit will be available until 30 July 2026.Revisiting HIV Antiretroviral Drug Resistance in the Current Landscape: Expert Insights Into Cause, Consequence, and Clinical Approaches for Management In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/XAS865. CME credit will be available until 30 July 2026.Revisiting HIV Antiretroviral Drug Resistance in the Current Landscape: Expert Insights Into Cause, Consequence, and Clinical Approaches for Management In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/XAS865. CME credit will be available until 30 July 2026.Revisiting HIV Antiretroviral Drug Resistance in the Current Landscape: Expert Insights Into Cause, Consequence, and Clinical Approaches for Management In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/XAS865. CME credit will be available until 30 July 2026.Revisiting HIV Antiretroviral Drug Resistance in the Current Landscape: Expert Insights Into Cause, Consequence, and Clinical Approaches for Management In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.
BUFFALO, NY - April 11, 2025 – A new research perspective was published in Oncotarget, Volume 16, on April 4, 2025, titled “GSK3β activation is a key driver of resistance to Raf inhibition in BRAF mutant melanoma cells." In this work, first author Diana Crisan and corresponding author Abhijit Basu from the University Hospital Ulm led a team that presents experimental evidence pointing to the protein GSK3β as a key contributor to drug resistance in melanoma. Their findings suggest that GSK3β becomes increasingly active in cancer cells during treatment, helping them survive and adapt despite ongoing therapy with BRAF inhibitors. Melanoma is a type of skin cancer in which nearly half of patients have mutations in the BRAF gene that accelerate tumor growth. While treatments targeting BRAF, known as BRAF inhibitors, initially work well, tumors often find ways to fight back. This research perspective explores how GSK3β, a protein involved in metabolism and cell survival, becomes more active in melanoma cells that develop resistance to BRAF inhibitors. Researchers treated melanoma cells with a common BRAF mutation using Dabrafenib, a widely used BRAF inhibitor. Over time, the cancer cells developed resistance and showed a marked increase in GSK3β levels. This pattern was confirmed across multiple melanoma cell models, suggesting that the finding is consistent and reliable. Importantly, the researchers observed that treating resistant cancer cells with a GSK3β inhibitor significantly reduced their growth. This result suggests that blocking this protein could restore sensitivity to treatment, highlighting GSK3β as a promising therapeutic target and supporting the idea of combining GSK3β inhibitors with existing melanoma therapies. “Remarkably, treatment of BRAFi-resistant melanoma cells with the GSK3 inhibitor LY2090314 for three weeks could overcome resistance and significantly decreased melanoma cell growth, confirming the causal role of GSK3 activation for BRAFi resistance development.” The research perspective adds to ongoing efforts to understand and overcome melanoma drug resistance. It shows that resistance is not driven only by genetic mutations but may also involve adaptive changes in the cell's internal signaling and survival mechanisms. By identifying GSK3β as a potential contributor, the authors offer a new direction for improving the durability of targeted treatments in melanoma. As research continues, GSK3β may be a critical factor in the long-term success of melanoma therapy, particularly for patients who have stopped responding to standard BRAF-targeted drugs. Continue reading: DOI: https://doi.org/10.18632/oncotarget.28711 Correspondence to: Abhijit Basu — abhijit.basu@alumni.uni-ulm.de Video short - https://www.youtube.com/watch?v=G2Tq4_r6xLw Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science). To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM
TWiP explains a study that carries out selection of Plasmodium falciparum in the presence of inhibitors to identify determinants of drug resistance, and a paleoparasitological analysis of a 5th–16th c. CE latrine. Hosts: Vincent Racaniello, Daniel Griffin, and Christina Naula Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Links for this episode Join the MicrobeTV Discord server Naegleria fowleri acquired at splash pad (MMWR) Determinants of P. falciparum drug resistance (Science) Paleoparasitological analysis of 5th–16th c. CE latrine (Parasitol) Become a patron of TWiP Send your questions and comments to twip@microbe.tv Music by Ronald Jenkees
In this episode of Going anti-Viral, Dr Michael Saag speaks with Dr Annemarie M. Wensing, a Clinical Virologist at the University Medical Center Utrecht and an Honorary Professor at the University of the Witwatersrand in Johannesburg. Dr Wensing joins Dr Saag to discuss the recently released IAS–USA 2025 Update of the Drug Resistance Mutations in HIV-1. Dr Wensing discusses the influence of Dr Charles Boucher in developing her interest in the topic of HIV drug resistance and Dr Wensing and Dr Saag provide an overview of HIV drug resistance and testing. Dr Wensing also provides advice to clinicians on how to manage patients who experience drug resistance. Dr Wensing and Dr Saag then discuss an upcoming report soon to be published that addresses the potential role and the important limitations of HIV DNA resistance testing. Finally, they address the topic of drug resistance in the absence of resistance mutations and look ahead to what the future holds for the field of HIV resistance. 0:00 – Introduction 1:30 – Dr Wensing reviews the influence that Dr Charles Boucher played in her development as an investigator and her interest in HIV resistance 2:46 – Discussion of why there is HIV drug resistance 4:48 – Overview of drug resistance testing, genotypes and phenotypes 7:25 – New recommendations from the IAS-USA resistance mutation panel 9:50 – Advice to clinicians on managing drug resistance 16:16 – Discussion of HIV DNA resistance testing 21:26 – Understanding drug failure in the absence of resistance mutations 24:49 – Predictions about the future Resources: IAS–USA Drug Resistance Mutations Chart: https://www.iasusa.org/hiv-drug-resistance/hiv-drug-resistance-mutations/ __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...
In this conversation, Ryan Maves and Dennis discuss various aspects of tuberculosis, including recent outbreaks, public health implications, and treatment protocols. They delve into the complexities of managing tuberculosis in different contexts, particularly within military settings, and highlight the importance of public health initiatives like PEPFAR. The discussion also touches on the challenges posed by drug-resistant tuberculosis and the evolving landscape of health policy. In this conversation, Ryan Maves discusses the complexities of tuberculosis (TB), including its historical significance, transmission methods, diagnosis, treatment protocols, and the challenges posed by drug resistance. He emphasizes the importance of public health measures in managing TB outbreaks and reassures that most individuals with TB can recover with appropriate treatment. The discussion also highlights the role of good ventilation in reducing transmission risk and the need for awareness and screening in military and public health settings.TakeawaysTuberculosis outbreaks can be slow and complex, not immediate crises.Public health interventions are crucial for effective tuberculosis management.PEPFAR has saved millions of lives and is a significant achievement in global health.Drug-resistant tuberculosis presents unique challenges in treatment.Telemedicine can enhance the management of tuberculosis in remote settings.Understanding the transmission dynamics of tuberculosis is essential for prevention.Good ventilation and treatment protocols can mitigate tuberculosis risks.Public health policies can significantly impact disease control efforts.Collaboration and open dialogue are necessary for effective health policy.The importance of recognizing the long-term nature of tuberculosis management. Tuberculosis is a significant global health issue that has been impacted by the COVID-19 pandemic.HIV and tuberculosis have a close interaction, affecting incidence and outcomes.Active screening for tuberculosis is crucial, especially in military settings.Good ventilation and sunlight can significantly reduce the risk of TB transmission.Latent TB infection can progress to active disease if not treated promptly.The classic treatment regimen for active TB involves a combination of four drugs.Multi-drug resistant TB (MDR-TB) is a growing concern, particularly in certain regions.Rifampin is a key drug in TB treatment but has notable drug interactions.Most people with TB can recover with effective therapy, and treatment is often satisfying for healthcare providers.Public health measures are essential in managing TB outbreaks and ensuring community safety.Chapters00:00 Introduction and Personal Updates03:11 Understanding Tuberculosis Outbreaks06:00 Public Health and Policy Implications08:54 PEPFAR and Global Health Initiatives12:00 Tuberculosis in Military Contexts14:58 Diagnosis and Treatment of Tuberculosis18:01 Drug-Resistant Tuberculosis23:15 Understanding Tuberculosis: A Global Perspective27:43 Transmission and Infection: How TB Spreads33:31 Diagnosis and Screening: Identifying TB Cases41:41 Treatment Protocols: Managing Active and Latent TB51:29 Challenges of Drug Resistance in TB58:03 Public Health Response: Reporting and Managing OutbreaksThank you to Delta Development Team for in part, sponsoring this podcast.deltadevteam.comFor more content go to www.prolongedfieldcare.orgConsider supporting us: patreon.com/ProlongedFieldCareCollective or www.lobocoffeeco.com/product-page/prolonged-field-care
BUFFALO, NY - February 6, 2025 – A new #casereport was #published in Volume 16 of Oncotarget on February 5, 2025, titled “Acquired RUFY1-RET rearrangement as a mechanism of resistance to lorlatinib in a patient with CD74-ROS1 rearranged non-small cell lung cancer: A case report." In this case report, Jenny L. Wu from Vanderbilt University School of Medicine and Wade T. Iams from Vanderbilt-Ingram Cancer Center describe a rare case of drug resistance in a patient with advanced non-small cell lung cancer (NSCLC). The patient, a 42-year-old man who had never smoked, initially responded well to lorlatinib, a targeted therapy designed to treat cancer driven by specific genetic alterations. However, after six months, his cancer began to grow again. Clinicians discovered that this was due to a new genetic change, known as the RUFY1-RET fusion. This finding highlights how cancers can adapt to treatment and the importance of ongoing genetic testing to guide therapy decisions. NSCLC is the most common type of lung cancer, and in some cases, it is driven by genetic changes that can be targeted with specific drugs. The patient's cancer originally had a ROS1 gene rearrangement, which made it responsive to lorlatinib. But as time went on, the cancer started to grow again, and tests revealed a new genetic alteration called RUFY1-RET fusion, which likely caused resistance to lorlatinib. This new genetic change was identified using RNA next-generation sequencing (RNA NGS), an advanced test that can find mutations that standard genetic tests might miss. After discovering the RUFY1-RET gene fusion, the patient was treated with a combination of lorlatinib and pralsetinib, a drug that specifically targets RET gene alterations. While this combination helped control the cancer for about four months, the patient's condition unfortunately worsened after four months. “This is the first reported case of a RET fusion as a potential mechanism of resistance to lorlatinib, it identifies a novel RET fusion partner, and it emphasizes the importance of testing for acquired resistance mutations with both DNA and RNA at the time of progression in patients with targetable oncogenic drivers.” Understanding cases like this can help clinicians and researchers develop more effective treatment strategies, including combination therapies that target multiple genetic changes to combat drug resistance. While the combined therapy in this case provided only temporary benefits, it offers important insights for future research and patient care, particularly for cancers that no longer respond to standard treatments. DOI: https://doi.org/10.18632/oncotarget.28682 Correspondence to: Wade T. Iams, wade.t.iams@vumc.org Keywords: cancer, ROS1 rearrangement, RET rearrangement, non-small cell lung cancer, targeted therapy, case report Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science). To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM
In this episode of Microbe Talk Clare spoke to Adam Aspinall who's Senior Director in the Access and Product Management team at Medicines for Malaria Venture. They discuss Malaria, antimalarial drug resistance and the work that Medicines for Malaria Venture is doing to support new drug discovery.If you'd like to find out more about the Microbiology Society's Knocking Out AMR project, you can do so here.If you'd like to find out more about the work that Medicines for Malaria do, take a look at their resources here: MMV website: http://mmv.orgSevere Malaria Observatory : severemalaria.orgMusic: Blue Dot Sessions - Blue Latex
How has drug resistance been addressed in the field of oncology? In this episode, Adam Torres and John Yu, CEO & Chairman at Kairos Pharma, Ltd., explore drug resistance and Kairos Pharma, Ltd. Follow Adam on Instagram at https://www.instagram.com/askadamtorres/ for up to date information on book releases and tour schedule. Apply to be a guest on our podcast: https://missionmatters.lpages.co/podcastguest/ Visit our website: https://missionmatters.com/ More FREE content from Mission Matters here: https://linktr.ee/missionmattersmedia
How has drug resistance been addressed in the field of oncology? In this episode, Adam Torres and John Yu, CEO & Chairman at Kairos Pharma, Ltd., explore drug resistance and Kairos Pharma, Ltd. Follow Adam on Instagram at https://www.instagram.com/askadamtorres/ for up to date information on book releases and tour schedule. Apply to be a guest on our podcast: https://missionmatters.lpages.co/podcastguest/ Visit our website: https://missionmatters.com/ More FREE content from Mission Matters here: https://linktr.ee/missionmattersmedia Learn more about your ad choices. Visit megaphone.fm/adchoices
Zach Hornby, CEO of San Diego-based Boundless Bio, on tackling cancer drug resistance.
First, Indian Express' Diplomatic Affairs Editor Shubhajit Roy discusses the recent coordinated attacks in Lebanon, where thousands of pagers and hand-held radios exploded, resulting in at least 37 deaths and over 3,500 injuries. He explains the implications for the region and the concerns it raises for New Delhi.Next, Indian Express' Anonna Dutt highlights the rising threat of antimicrobial resistance and addresses common misconceptions about antibiotics (10:36).Finally, we hear from Indian Express' Nihal Koshie talks about Olympic wrestler Vinesh Phogat's transition into politics (21:25).Further listening: Vinesh Phogat transitions from mat to political stageHosted and written by Shashank BhargavaProduced by Shashank Bhargava and Ichha Sharma
Dr. Aileen Marty, Infectious Disease Specialist and Professor at Florida International University, joins Bob Sirott to talk about the latest health news. Dr. Marty discusses the development of an antibiotic that would make it difficult to develop a drug resistance and when we could see it at the doctor’s office.
The problem of antimicrobial resistance – AMR for short – is clear. More and more of these germs resistant to existing treatments are emerging everywhere, and there's little disagreement that governments, nonprofits, doctors, patients, and politicians all need to help tackle the problem.But people need to agree on what to do, and they need to agree on how to measure progress.That's where targets come in.Aislinn Cook, a senior research fellow in infectious disease epidemiology on the antimicrobial resistance team in the Centre for Neonatal and Pediatric Infection of St. George's University in London, is helping set some of those targets. Cook, who's also affiliated with the Health Economics Research Centre at the University of Oxford, has helped write a series of papers in the Lancet medical journal bringing attention to the problem of antimicrobial resistance. AMR is a big topic of international discussion in 2024, due in part to it being one of the topics of the United Nations High-Level Meeting, and the Lancet series was put together to help focus that discussion.Cook's paper proposes some clear targets to reach by 2030: a 10 percent reduction in mortality from drug-resistant infections; a 20 percent reduction in inappropriate human antibiotic use; and a 30 percent reduction in inappropriate animal antibiotic use.These goals should be achievable, Cook says. Listen as she tells One World, One Health about some concrete ways the world can work together to control the spread of drug-resistant germs.Learn more about the struggle to control drug-resistant bacteria, viruses, and fungi in some of our other episodes. We've spoken with experts about how vaccines can help prevent the spread of drug-resistant germs, about tracking superbugs in sewage, and the surprising rise of drug-resistant fungi. Experts in drug design have talked to us about the search for new and better antibiotics and how these little organisms are winning an arms race against us. Filmmakers have told us about how storytelling can help people understand the threat while global health specialists explained that good stewardship can keep the antibiotics we have working as they should. We've even investigated superbug mysteries, like the case of the killer eyedrops.
In this episode, we review the high-yield topic of Drug Resistance from the Microbiology section. Follow Medbullets on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets --- Send in a voice message: https://podcasters.spotify.com/pod/show/medbulletsstep1/message
In this episode, host Alyssa Watson, DVM, talks to Ray M. Kaplan, DVM, PhD, DEVPC, DACVM (Parasitology), about his recent Clinician's Brief article, “Diagnosing Drug Resistance in Canine Hookworms via Fecal Egg Count Reduction Test.” Resistant hookworms are no longer uncommon, so Dr. Kaplan joined us to break it down. He details how to diagnose resistance by comparing pretreatment and 14-day posttreatment egg counts using a fecal egg count reduction test. Dr. Kaplan then explains how and when to use “triple therapy” in cases when resistance is confirmed.Sponsored by Merck Animal HealthResource:https://www.cliniciansbrief.com/article/hookworm-dogs-drug-resistance-diagnosishttps://www.cliniciansbrief.com/article/persistent-or-suspected-resistant-hookworm-infectionshttps://UnlockBetterProtection.comContact us:Podcast@briefmedia.comWhere to find us:Youtube.com/@clinicians_briefCliniciansbrief.com/podcastsFacebook.com/cliniciansbriefTwitter: @cliniciansbriefInstagram: @clinicians.briefThe Team:Alyssa Watson, DVM - HostAlexis Ussery - Producer & Multimedia Specialist
It's not a worm, it's a fungus among us. Today's topic is ringworm. Joining me today is Regents Professor of Clinical Laboratory Science at Texas State University and author of an article published in The Conversation last year, but a topic still worth discussing. Ringworm fungal infections are common in the US and are becoming increasingly resistant to treatment
Drug-resistant infections are a problem for everyone, but especially for newborns. They don't have fully developed immune systems, and their bodies are less equipped to fight infections.The risk is highest for infants born sick or prematurely. Bloodborne infections – sepsis – are one major threat to newborns. Sepsis can move quickly, overpowering the body and causing severe illness and even death within hours. Doctors don't have time to test babies to see what's infecting them and have to treat them based on what Dr. Mike Sharland calls a best guess. These infections are often resistant to the drugs that are available to treat them, too. National and international guidelines can help doctors make difficult and life-altering decisions about treatment, but there's not much guidance for health professionals treating newborns. That's in part because there is so little research on which antibiotics work in newborns. Sharland, a pediatric infectious disease specialist at St George's University of London, is helping lead a group running the clinical trials needed to form the basis of guidelines.In this episode, Dr. Sharland tells us about the terrifying growth of drug-resistant infections in newborns and the need for better antibiotics for these vulnerable babies.
Brazil's Proactive Measures Against HIVBrazil has been at the forefront of combating HIV, implementing proactive measures that have made a significant difference. The country began providing no-cost access to CD4 and viral load testing and antiretroviral drugs as early as 1996. This early intervention and consistent approach led to a remarkable outcome: the number of HIV cases in Brazil was significantly lower than initially predicted. An article from the New England Journal of Medicine stated that initial estimates predicted Brazil would have 1.2 million people infected with HIV by the year 2000, but with the strategies the country put in place, their actual numbers were about half of what was predicted. By offering free access to treatments and diagnostic tests, Brazil showcased the importance of early and sustained intervention in managing and reducing the spread of HIV. The Rising Challenge of HIV Drug ResistanceOne of the most pressing challenges in the fight against HIV is the development of drug resistance. Dr. Ricardo Diaz emphasizes that as the HIV virus replicates, it can produce strains resistant to treatment. This resistance threatens the efficacy of antiretroviral drugs, making it crucial to monitor and manage. The World Health Organization reports an increasing rate of HIV drug resistance, underscoring the need for continuous research, monitoring, and adaptation of treatment strategies. Pre-exposure Prophylaxis (PrEP) Drugs Exist, but are not 100% EffectivePrEP, or pre-exposure prophylaxis, is also an antiretroviral drug given to uninfected individuals who are at risk of infection to reduce their chances of acquiring HIV. PrEP is highly effective at preventing HIV when taken as indicated, but much less effective when it isn't taken consistently. Additionally, it's possible to be exposed to HIV strains that are drug resistant while on PrEP, so monitoring resistance in people on PrEP is another important step in prevention. The Gap in HIV Drug Resistance TestingDespite the advancements in treatment, there's a noticeable disparity in HIV drug resistance testing, especially in Brazil. Dr. Diaz highlights that while a centralized lab in Brazil performs genotype testing, the number of tests conducted falls short of the actual need. With 10% of patients on treatment showing a viral load above the desired limit, the demand for resistance testing is evident. Bridging this gap and increasing surveillance efforts is essential to tailor treatments effectively and combat the spread of drug-resistant HIV strains.
Vaccines are lifesavers. Childhood vaccines save 4 million lives every year, according to the US Centers for Disease Control and Prevention. And it turns out vaccines don't just save lives by directly preventing disease. They can save lives by reducing the rise of drug-resistant pathogens (mostly bacteria and viruses). This is because people who are vaccinated are less likely to get sick and to get treated either appropriately or inappropriately with antibiotics and antiviral drugs. And less use of these valuable drugs means less opportunity for germs to develop resistance to them. The One Health Trust set out to quantify just how well vaccination could reduce the emergence and spread of antimicrobial resistance or drug-defying germs. The latest report from the One Health Trust pulls together a variety of studies showing the impact of vaccines not only on drug resistance but also on economies, especially in low- and middle-income countries. Some highlights: A typhoid vaccination campaign for infants could prevent more than 53 million cases of drug-resistant typhoid in low- and middle-income countries over 10 years. A successful rotavirus vaccination program in Africa and Asia could prevent more than 13 million cases of diarrhea that otherwise would be treated with antibiotics – reducing opportunities for bacteria to evolve resistance to those drugs. In Indonesia alone, vaccinating 50% of eligible people with pneumococcal vaccine over five years could save more than US$2 million in costs related to treatment failure. One Health Trust Fellow and Director of Partnerships, Dr. Erta Kalanxhi, led the team that put together the report. Listen as she chats with One World, One Health host Maggie Fox about how vaccines can prevent the rise of drug-resistant bacteria and viruses.
Drug-defying superbugs can be found in manure, soil, the ocean, and especially in sewers. These places are sources of infection, but they also provide a way to keep an eye on which drug-resistant germs are where – and how much they are changing. The World Health Organization encourages mapping all of the places drug-resistant organisms are popping up, and what kind of organisms there are. “If no action is taken, AMR (antimicrobial resistance) could cost the world's economy US$ 100 trillion by 2050,” WHO says. Windi Muziasari, PhD, became passionate about tracking these deadly germs while doing postdoctoral research at the University of Helsinki in Finland. The Indonesian-born scientist founded her own company to do this mapping for governments, communities, and companies. As Founder and CEO of ResistoMap, Muziasari has looked for drug-resistant microbes in agricultural runoff, in hospitals, under city streets, among wildlife, and elsewhere in dozens of countries. The hope is to act as an early warning system so that companies, governments, and others can do something about the problem. “Almost everywhere is polluted,” she tells us on the One World, One Health podcast. Listen as Windi Muziasari tells host Maggie Fox about how and why she got started and what she's learned since launching ResistoMap.
In this episode, Shannon Kasperbauer, MD, discusses guideline-based treatment recommendations for people with M. abscessus, including a discussion of:Macrolide resistancePredictors for disease progression2020 NTM guideline recommended treatment optionsEmerging therapiesWe will also hear from a patient who describes how she remained adherent during long courses of treatment for M. abscessus.Finally, we hear Dr Kasperbauer discuss a patient case with her colleagues, Charles L. Daley, MD, and Pamela J. McShane, MD.Presenters:Charles L. Daley, MDProfessor of MedicineDivision of Mycobacterial and Respiratory Infections National Jewish HealthDenver, ColoradoShannon Kasperbauer, MDAssociate Professor of MedicineDivision of Mycobacterial and Respiratory InfectionsNational Jewish HealthDenver, ColoradoPamela J. McShane, MDProfessor of MedicineDivision of Pulmonary and Critical Care MedicineThe University of Texas Health Science Center at TylerTyler, TexasLink to program page: https://bit.ly/3QzJo2BLink to downloadable slides: https://bit.ly/3Qh8T7G
BUFFALO, NY- October 11, 2023 – A new research paper was published in Oncotarget's Volume 14 on October 4, 2023, entitled, “Inhibiting BRAF/EGFR/MEK suppresses cancer stemness and drug resistance of primary colorectal cancer cells.” Drug resistance is a major barrier against successful treatments of cancer patients. Gain of stemness under drug pressure is a major mechanism that renders treatments ineffective. Identifying approaches to target cancer stem cells (CSCs) is expected to improve treatment outcomes for patients. In their new study, researchers Astha Lamichhane, Gary D. Luker, Seema Agarwal, and Hossein Tavana from The University of Akron, University of Michigan and Georgetown University aimed to elucidate the role of cancer stemness in resistance of colorectal cancer cells to targeted therapies. “[...] we developed spheroid cultures of patient-derived BRAFmut and KRASmut tumor cells and studied resistance mechanisms to inhibition of MAPK pathway through phenotypic and gene and protein expression analysis.” They found that treatments enriched the expression of CSC markers CD166, ALDH1A3, CD133, and LGR5 and activated PI3K/Akt pathway in cancer cells. The team examined various combination treatments to block these activities and found that a triple combination against BRAF, EGFR, and MEK significantly reduced stemness and activities of oncogenic signaling pathways. This study demonstrates the feasibility of blocking stemness-mediated drug resistance and tumorigenic activities in colorectal cancer. “Our approach to identify mechanisms of drug resistance of patient-derived cancer cells to targeted therapies and develop effective treatments is promising toward cancer precision medicine.” DOI - https://doi.org/10.18632/oncotarget.28517 Correspondence to - Hossein Tavana - tavana@uakron.edu Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28517 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, drug resistance, cancer stem cells, patient-derived tumor model, colorectal cancer, combination treatment About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957
Are you tired of the same old cancer treatment methods that leave you feeling drained and hopeless? Look no further than the Integrative Cancer Solutions with Dr. Karlfeldt. In our latest episode, we have Dr. Stephen Iacoboni, a medical oncologist with over 40 years of experience, discussing the use of naturopathic remedies alongside chemotherapy to overcome drug resistance. Our goal is to educate and inform our listeners about alternative cancer solutions that have been successful for others. Dr. Iacoboni shares his expertise in integrative oncology and explains why he believes that academic institutions have a primary mission of research, while a doctor in the community has a primary mission of patient care. The conversation also touches on the pros and cons of chemotherapy and the emerging direction of immunotherapy. Join us as we explore the history and progress of cancer treatment, breakthroughs in oncology, and alternative tools and treatments. Don't miss out on this informative and eye-opening episode. Tune in to Integrative Cancer Solutions with Dr. Karlfeldt today.- Alternative cancer treatments- Naturopathic remedies- Integrative oncology- Evolution of medical oncology- Pros and cons of chemotherapy- Immunotherapy limitations- Insulin Potentiated Therapy- Hyperoxidative therapy- Exploiting cancer cell vulnerabilities- Antioxidants and cancer- Nutraceuticals in cancer treatment- Revolution in oncology- Telos book and purpose in life- Scientific atheism and faith- Patient-centered care- Educational purposes only- Karlfeldt Center promotionKEY POINTS[0:0:32] With integrative and holistic methods, it's possible to WIN the fight against cancer.[0:5:16] Academic institutions are dedicated to pushing the boundaries of knowledge, while doctors are devoted to providing life-saving care to their patients.[0:8:53] In the last four decades, medical oncology has seen a remarkable transformation, from primitive radiation and surgical treatments to the development of revolutionary chemotherapy and immunotherapy treatments.[0:14:22] Shockingly, traditional cancer therapies often come with debilitating side effects - but luckily, there are now alternative solutions available![0:16:44] Miraculously, over 90% of early stage cancer cases can be successfully cured – giving hope to those facing the devastating diagnosis of stage four cancer.[0:21:39] By strategically targeting the oxidative state of cancer cells with Vitamin C and K3 at a specific ratio, researchers have uncovered an incredibly empowering and overlooked vulnerability in the fight against cancer.[0:22:10] Chemotherapy is a much less lethal and more effective alternative to Cyanide for treating cancer, with the power to eradicate cancerous cells on a much larger scale.[0:26:25] Cancer cells exhibit an alarming, frenetic energy level, devouring vast amounts of energy to fuel their rapid growth.[0:27:42] By leveraging the power of Prooxidants, cancer cells can be efficiently destroyed with reduced chemo doses, effectively cutting off their crucial supply of antioxidants![0:30:20] Despite the exorbitant price of cancer medications, some physicians prioritize patient health above profit, delivering effective and accessible treatments to improve the lives of those affected.[0:36:22] By revolutionizing oncology, we could dramatically reduce Medicare costs, saving billions of dollars and dramatically improving the lives of countless patients.[0:46:24] Incredibly, nutraceuticals with hyperoxidation properties have the potential to halt the progression of pre-cancerous cells, offering a cost-effective alternative to traditional cancer prevention methods. Connect with Stephen at https://stepheniacoboni.com/ Integrative Cancer Solutions was created to instill hope and empowerment. Other people have been where you are right now and have already done the research for you. Listen to their stories and journeys and apply what they learned to achieve similar outcomes as they have, cancer remission and an even more fullness of life than before the diagnosis. Guests will discuss what therapies, supplements, and practitioners they relied on to beat cancer. Once diagnosed, time is of the essence. This podcast will dramatically reduce your learning curve as you search for your own solution to cancer. For more information about products and services discussed in this podcast, please visit www.integrativecancersolutions.com. To learn more about the cutting-edge integrative cancer therapies Dr. Karlfeldt offer at his center, please visit www.TheKarlfeldtCenter.com.
Madeleine Finlay speaks to Guardian science correspondent Linda Geddes about the possibility of a fungal pandemic like the one depicted in apocalyptic thriller The Last of Us. They discuss the strange world of fungi, the risks of infections and treatment resistance, and what we can do to protect ourselves from future fungal threats. Help support our independent journalism at theguardian.com/sciencepod
© 2020-2026 Ivy Podcast Discovery LLC
